Sarepta Therapeutics, Inc. (SRPT)
Company Info
| ISIN | US8036071004 |
|---|---|
| CUSIP | 803607100 |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | Jun 3, 1997 |
Highlights
| Market Cap | $10.92B |
|---|---|
| EPS (TTM) | $1.54 |
| PE Ratio | 74.23 |
| PEG Ratio | 159.25 |
| Total Revenue (TTM) | $1.64B |
| Gross Profit (TTM) | $1.40B |
| EBITDA (TTM) | $70.22M |
| Year Range | $78.67 - $173.25 |
| Target Price | $189.05 |
| Short % | 6.13% |
| Short Ratio | 7.15 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: SRPT vs. WULF, SRPT vs. COST, SRPT vs. NTRA, SRPT vs. ASM, SRPT vs. INSM, SRPT vs. DAVE, SRPT vs. ML, SRPT vs. SPY, SRPT vs. CLS, SRPT vs. ANF
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Sarepta Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Sarepta Therapeutics, Inc. had a return of 16.64% year-to-date (YTD) and 36.34% in the last 12 months. Over the past 10 years, Sarepta Therapeutics, Inc. had an annualized return of 22.12%, outperforming the S&P 500 benchmark which had an annualized return of 11.39%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 16.64% | 25.48% |
| 1 month | -9.56% | 2.14% |
| 6 months | -15.11% | 12.76% |
| 1 year | 36.34% | 33.14% |
| 5 years (annualized) | 2.92% | 13.96% |
| 10 years (annualized) | 22.12% | 11.39% |
Monthly Returns
The table below presents the monthly returns of SRPT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 23.40% | 7.49% | 1.22% | -2.16% | 2.53% | 21.67% | -9.97% | -4.54% | -8.02% | 0.89% | 16.64% | ||
| 2023 | -3.56% | -2.27% | 12.86% | -10.93% | 0.68% | -7.35% | -5.35% | 11.64% | 0.17% | -44.47% | 20.75% | 18.64% | -25.58% |
| 2022 | -20.52% | 7.04% | 1.97% | -7.42% | 0.69% | 2.94% | 24.00% | 17.68% | 1.06% | 3.15% | 7.71% | 5.51% | 43.90% |
| 2021 | -47.56% | -2.62% | -14.39% | -4.95% | 6.79% | 2.76% | -12.81% | 15.26% | 18.38% | -14.44% | 2.12% | 11.43% | -47.18% |
| 2020 | -10.14% | -1.28% | -14.55% | 20.51% | 29.17% | 5.30% | -4.25% | -4.62% | -4.09% | -3.22% | 3.64% | 21.04% | 32.12% |
| 2019 | 28.02% | 3.24% | -17.37% | -1.89% | -2.64% | 33.47% | -2.04% | -39.44% | -16.45% | 10.28% | 35.43% | 14.71% | 18.24% |
| 2018 | 17.79% | -4.23% | 18.03% | 3.06% | 22.90% | 40.84% | -12.06% | 18.75% | 17.00% | -17.18% | -3.21% | -15.71% | 96.14% |
| 2017 | 13.23% | 0.16% | -4.85% | 22.50% | -17.71% | 12.97% | 14.45% | 4.43% | 12.58% | 8.71% | 12.90% | -0.05% | 102.84% |
| 2016 | -69.21% | 15.40% | 42.38% | -27.31% | 47.50% | -8.89% | 32.56% | 3.12% | 135.56% | -36.10% | -12.69% | -19.94% | -28.90% |
| 2015 | -17.07% | 15.83% | -4.46% | -8.13% | 110.00% | 18.77% | 4.90% | 11.84% | -10.06% | -25.07% | 52.78% | 4.95% | 166.62% |
| 2014 | 19.69% | 19.07% | -17.22% | 54.52% | -9.29% | -11.55% | -28.37% | 7.45% | -7.98% | -23.36% | 4.76% | -14.58% | -28.96% |
| 2013 | 4.84% | 8.30% | 26.13% | -21.41% | 21.73% | 7.61% | -2.78% | -7.71% | 38.38% | -17.61% | -52.10% | 9.28% | -21.05% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of SRPT is 68, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Sarepta Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sarepta Therapeutics, Inc. was 98.17%, occurring on Dec 18, 2008. Recovery took 2458 trading sessions.
The current Sarepta Therapeutics, Inc. drawdown is 37.07%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.17% | Feb 10, 2000 | 2228 | Dec 18, 2008 | 2458 | Sep 26, 2018 | 4686 |
| -73.03% | Oct 8, 1997 | 358 | Mar 11, 1999 | 216 | Jan 18, 2000 | 574 |
| -64.93% | Dec 23, 2020 | 373 | Jun 16, 2022 | — | — | — |
| -54.92% | Oct 1, 2018 | 249 | Sep 26, 2019 | 182 | Jun 17, 2020 | 431 |
| -27.14% | Jul 21, 2020 | 79 | Nov 9, 2020 | 28 | Dec 18, 2020 | 107 |
Volatility
Volatility Chart
The current Sarepta Therapeutics, Inc. volatility is 9.67%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Sarepta Therapeutics, Inc. compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for SRPT in comparison to other companies of the Biotechnology industry. Currently, SRPT has a PE value of 74.2. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for SRPT in comparison to other companies of the Biotechnology industry. Currently, SRPT has a PEG value of 159.3. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Sarepta Therapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |